New drug aims to boost insulin sensitivity and muscle health in diabetes
NCT ID NCT07137585
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a drug called RO7204239 can improve how the body uses insulin and affects muscle composition in 30 adults with type 2 diabetes who are overweight or obese. Participants will receive either the drug or a placebo, and researchers will measure changes in insulin sensitivity and blood sugar control over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RO7204239 (also called GYM329)
What this could lead to
If it works, this could point toward a new treatment that helps control blood sugar and improve muscle function in people with type 2 diabetes.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so results may not apply to everyone. The drug may not improve insulin sensitivity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil Institut für Stoffwechselforschung
Homburg, Saarland, 66421, Germany